Skip to main content
ARS Home » Midwest Area » Ames, Iowa » National Animal Disease Center » Infectious Bacterial Diseases Research » Research » Publications at this Location » Publication #230785
Title: Protection Against Fowl Cholera Conferred by Recombinant Pasteurella Multocida Filamentous Hemmagglutinin

Author
item Tatum, Fred
item Tabatabai, Louisa
item Briggs, Robert

Submitted to: Meeting Abstract
Publication Type: Abstract Only
Publication Acceptance Date: 9/25/2008
Publication Date: 10/25/2008
Citation: Tatum, F.M., Tabatabai, L.B., Briggs, R.E. 2008. Protection Against Fowl Cholera Conferred by Recombinant Pasteurella Multocida Filamentous Hemmagglutinin [abstract]. Conference for Research Workers in Animal Disease. Abstract No. 111. p. 123.

Interpretive Summary:

Technical Abstract: Pasteurella multocida is a gram negative bacterium associated with a wide range of diseases in animals. In this study, three gene fragments encoding approximately the 5' one-third of fhaB2 (filamentous hemagglutinin) were derived from P. multocida P-1059 (a highly pathogenic strain in avian species) and expressed individually in Escherichia coli. The recombinant peptides were purified, pooled and administered in a commercial adjuvant to turkey poults to evaluate protective immunity. The results showed that turkeys immunized twice with recombinant peptides were significantly protected against intranasal challenge with P. multocida strain P-1059. Fourteen of seventeen vaccinates and zero of seventeen controls survived. Vaccination elicited antibody responses, based on Western blotting, which were reactive to a cellular product approximately 170 kDa in size and multiple high molecular weight products in the culture supernatant. These antibodies reacted with wild-type P-1059 but with an isogenic fhaB2 mutant. The FHAB2 proteins of a bovine (A:3) and avian strains (F:3 and A:3) are highly conserved (>99% identity) suggesting that broad cross protection against this heterogeneous pathogen may be achievable through immunization with specific recombinant FHAB2 peptides.